Department of Nuclear Medicine and PET Center, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Department of Breast and Endocrine Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Jpn J Radiol. 2016 Mar;34(3):167-80. doi: 10.1007/s11604-015-0516-0. Epub 2016 Jan 5.
Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.
正电子发射断层扫描/计算机断层扫描（PET/CT）与 2-[18F]氟-2-脱氧-D-葡萄糖（FDG）的结合是一种有用的工具，可在单次诊断过程中使用单个设备同时获得葡萄糖代谢和解剖成像数据，为临床肿瘤成像开辟了新的领域。FDG-PET/CT 已成功用于乳腺癌以及各种恶性肿瘤的诊断、初始分期、再分期、早期治疗反应评估、转移性疾病反应评估和预后。本文综述了 FDG-PET/CT 在乳腺癌管理中的当前地位和作用，重点介绍了其在这些患者成像中的有用性和局限性。
